Chiauranib is a new molecular entity exclusively discovered by the company with global patent protection, featuring a novel mechanism as a triple-pathway tumor-targeting inhibitor. Chiauranib selectively inhibits protein kinase targets related to tumorigenesis and tumor development, including Aurora B, CSF1R, and VEGFR/PDGFR/c-Kit. It exerts multi-directional and broad-spectrum anti-tumor effects by inhibiting tumor cell proliferation, suppressing tumor angiogenesis, and regulating the tumor immune microenvironment, demonstrating favorable efficacy and safety in clinical trials of monotherapy for end-line tumor treatment.

With its highly selective inhibition of Aurora B/VEGFR/PDGFR/c-Kit/CSF1R targets, Chiauranib achieves comprehensive anti-tumor efficacy through three active mechanisms: inhibiting tumor cell mitosis/genomic stability, suppressing tumor angiogenesis, and modulating the tumor immune microenvironment. This multi-pathway mechanism results in superior pre-clinical pharmacodynamic activity compared to drugs with similar mechanisms and exhibits a favorable safety profile.

Figure Schematic Diagram of the Triple-Pathway Anti-Tumor Mechanism of Chiauranib

Global Pipeline of Investigational Indications:

• Pancreatic cancer (first-line): The Phase II trial of Chiauranib in combination with nab-paclitaxel and gemcitabine showed encouraging results. At a median follow-up of 13.2 months, the ORR was 52.4%, median progression-free survival (mPFS) was 9.3 months, and median OS had not yet been reached. Seven patients remained on treatment at the time of analysis.
• Pancreatic cancer (first-line): Enrollment in the lead-in phase of the Phase III clinical trial of Chiauranib in combination with toripalimab, nab-paclitaxel, and gemcitabine has been completed. The randomized controlled phase will begin following evaluation of the preliminary results.
• Ovarian cancer (platinum-refractory or platinum-resistant recurrence): Results from the Phase III randomized, double-blind, controlled trial of Chiauranib in combination with paclitaxel have been announced, and the data are currently being compiled and analyzed.
• U.S. Phase Ib: The Phase Ib clinical trial in the United States has been completed, and the recommended Phase II dose (RP2D) is currently under evaluation.